查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591893

人類胰島素製劑市場：按胰島素類型、輸送裝置、應用、分銷管道分類 - 全球預測 2025-2030

Human Insulin Drugs Market by Insulin Type (Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin), Delivery Devices (Insulin Pens, Insulin Pumps, Insulin Syringes), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年人類胰島素製劑市值為572.6億美元，預計2024年將達620.2億美元，複合年成長率為8.78%，到2030年將達到1032.2億美元。

人類胰島素產品市場包括用於調節糖尿病患者血糖值的胰島素產品的開發、製造和分銷。該系列包括多種形式的胰島素，包括速效、短效、中效和長效，以滿足不同的治療需求和患者偏好。由於人口老化、久坐的生活方式和飲食習慣等因素，全球糖尿病盛行率不斷上升，決定了對胰島素的需求。該應用程式主要專注於 1 型和 2 型糖尿病的管理，最終用戶包括醫院、診所和居家醫療機構。

主要市場統計
基準年[2023] 572.6億美元
預測年份 [2024] 620.2億美元
預測年份 [2030] 1032.2億美元
複合年成長率（%） 8.78%

市場的關鍵成長要素包括胰島素輸送系統（如胰島素筆、胰島素幫浦和人工胰臟裝置）的技術進步、患者依從性和療效的提高等。在歐洲和美國等地區，監管支持導致人們更加關注生物相似藥和具有成本效益的胰島素製劑，創造了巨大的商機。公司應考慮投資下一代胰島素研發和數位健康解決方案，以提高病人參與和個人化糖尿病管理策略。此外，向亞太地區和拉丁美洲等糖尿病人口不斷成長的新興市場擴張也提供了潛在的成長機會。

然而，市場面臨嚴格的法規環境和與創新胰島素療法相關的高開發成本等限制。此外，定價壓力和更便宜的學名藥的存在正在挑戰市場成長，並可能影響盈利。最佳創新領域包括超長效胰島素製劑的開發、智慧胰島素輸送系統的開發以及用於即時血糖監測和胰島素劑量的數位生態系統的整合。此外，病患教育和提高糖尿病管理意識是市場擴張的一條未被充分考慮的途徑。總體而言，該市場的特點是快速創新和激烈競爭，導致公司專注於合作夥伴關係和創新產品平臺，以保持競爭力並滿足不斷變化的糖尿病治療需求。

市場動態：揭示快速發展的人類胰島素市場的關鍵市場洞察

供需的動態交互作用正在改變人類胰島素市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球糖尿病患者數量不斷增加
    • 提高糖尿病患者生物仿製胰島素的可用性和採用率
    • 人類胰島素給藥系統的技術進展
  • 市場限制因素
    • 人類胰島素製劑的不良健康影響及相關的高成本
  • 市場機會
    • 持續研究開發新化合物和治療方法
    • 胰島素配方可能的改進與進步
  • 市場挑戰
    • 嚴格的核准規定和有限的供應

波特五力：駕馭人類胰島素市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對人類胰島素市場的影響

外部宏觀環境因素對人類胰島素製劑市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解人類胰島素製劑市場競爭狀況

對人類胰島素製劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人類胰島素製劑市場供應商績效評估

FPNV定位矩陣是評估人類胰島素製劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製人類胰島素製劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對人類胰島素製劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球糖尿病的盛行率正在上升
      • 提高糖尿病患者生物相似藥胰島素的可得性和採用率
      • 人類胰島素給藥系統的技術進展
    • 抑制因素
      • 對健康的不利影響和相關的高成本
    • 機會
      • 持續研究開發新化合物和治療方法
      • 胰島素配方的潛在改進和進步
    • 任務
      • 嚴格核准、限量供應監管標準
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以胰島素類型分類的人類胰島素製劑市場

  • 基礎或長效胰島素
  • 胰島素生物相似藥
  • 中效胰島素
  • 混合胰島素
  • 速效胰島素
  • 速效胰島素

第7章人類胰島素製劑市場分佈（按設備）

  • 胰島素筆
  • 胰島素幫浦
  • 胰島素注射器

第8章人類胰島素製劑市場：依應用分類

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第9章人類胰島素製劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章北美和南美人類胰島素製劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區人類胰島素製劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲人胰島素製劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 胰島素製造商Genesis投資5000-6000萬美元在海得拉巴建工廠
    • Humacyte 和 JDRF 合作開發產生胰島素的生物血管胰腺來治療第 1 型糖尿病
    • 禮來公司和 EVA Pharma 宣佈建立合作夥伴關係，以加強非洲永續獲得負擔得起的胰島素
  • 戰略分析和建議

公司名單

  • Albireo Pharma, Inc. by Ipsen
  • B. Braun Melsungen AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Eli Lilly and Company
  • Eris Lifesciences Ltd.
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Gulf Pharmaceutical Industries
  • Innova Life Sciences Private Limited
  • Lupin Limited
  • MannKind Corporation
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Shreya Life Sciences Pvt Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Limited
  • Zhuhai United Laboratories Co., Ltd.
Product Code: MRR-957C47F9221F

The Human Insulin Drugs Market was valued at USD 57.26 billion in 2023, expected to reach USD 62.02 billion in 2024, and is projected to grow at a CAGR of 8.78%, to USD 103.22 billion by 2030.

The human insulin drugs market encompasses the development, manufacturing, and distribution of insulin medications used to regulate blood sugar levels in people with diabetes. Its scope includes various forms such as rapid-acting, short-acting, intermediate-acting, and long-acting insulin, catering to different therapeutic needs and patient preferences. The necessity of insulin is dictated by the global rise in diabetes prevalence, driven by factors like aging populations, sedentary lifestyles, and dietary habits. Applications primarily focus on managing Type 1 and Type 2 diabetes, with end-users including hospitals, clinics, and homecare settings.

KEY MARKET STATISTICS
Base Year [2023] USD 57.26 billion
Estimated Year [2024] USD 62.02 billion
Forecast Year [2030] USD 103.22 billion
CAGR (%) 8.78%

Key growth influencers in the market include technological advancements in insulin delivery systems, such as insulin pens, pumps, and artificial pancreas devices, improving patient adherence and efficacy. The growing focus on biosimilars and cost-effective insulin options, driven by regulatory support in regions like Europe and the U.S., presents considerable opportunities. Companies should consider investing in research and development for next-generation insulin formulations and digital health solutions to increase patient engagement and personalized diabetes management strategies. Furthermore, expanding into emerging markets with rising diabetic populations, such as Asia-Pacific and Latin America, offers potential growth opportunities.

However, the market faces limitations, including stringent regulatory environments and high development costs associated with innovative insulin therapies. Additionally, market growth is challenged by pricing pressures and the presence of cheaper generic alternatives, which can affect profitability. The best areas for innovation include developing ultra-long-acting insulin varieties, smart insulin delivery systems, and integrating digital ecosystems for real-time glucose monitoring and insulin dosing. Also, enhancing patient education and awareness about diabetes management offers a less explored avenue for market expansion. Overall, as the market is characterized by rapid technological changes and strong competition, companies should focus on collaborative partnerships and innovative product pipelines to maintain a competitive edge and meet the evolving demands of diabetic care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Insulin Drugs Market

The Human Insulin Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of dibetic patient all over the globe
    • Increased availability and adoption of the biosimilar insulin among patients with diabetes
    • Technological advancements in human insulin drug delivery systems
  • Market Restraints
    • Adverse health impacts and associated high cost of human insulin drugs
  • Market Opportunities
    • Ongoing reserach activities for developments of new compounds and treatments
    • Potential improvements and advancement in the insulin formulations
  • Market Challenges
    • Stringent regulatory norms for approvals coupled with limited availability

Porter's Five Forces: A Strategic Tool for Navigating the Human Insulin Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Insulin Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Insulin Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Insulin Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Insulin Drugs Market

A detailed market share analysis in the Human Insulin Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Insulin Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Insulin Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Insulin Drugs Market

A strategic analysis of the Human Insulin Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Insulin Drugs Market, highlighting leading vendors and their innovative profiles. These include Albireo Pharma, Inc. by Ipsen, B. Braun Melsungen AG, Biocon Limited, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Eli Lilly and Company, Eris Lifesciences Ltd., Gan & Lee Pharmaceuticals Co., Ltd., Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries, Innova Life Sciences Private Limited, Lupin Limited, MannKind Corporation, Merck KGaA, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Shreya Life Sciences Pvt Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Limited, and Zhuhai United Laboratories Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Insulin Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Insulin Type, market is studied across Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin, Mixed Insulins, Rapid-Acting Insulin, and Short-Acting Insulin.
  • Based on Delivery Devices, market is studied across Insulin Pens, Insulin Pumps, and Insulin Syringes.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of dibetic patient all over the globe
      • 5.1.1.2. Increased availability and adoption of the biosimilar insulin among patients with diabetes
      • 5.1.1.3. Technological advancements in human insulin drug delivery systems
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts and associated high cost of human insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing reserach activities for developments of new compounds and treatments
      • 5.1.3.2. Potential improvements and advancement in the insulin formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory norms for approvals coupled with limited availability
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Insulin Drugs Market, by Insulin Type

  • 6.1. Introduction
  • 6.2. Basal or Long-Acting Insulins
  • 6.3. Biosimilar Insulins
  • 6.4. Intermediate-Acting Insulin
  • 6.5. Mixed Insulins
  • 6.6. Rapid-Acting Insulin
  • 6.7. Short-Acting Insulin

7. Human Insulin Drugs Market, by Delivery Devices

  • 7.1. Introduction
  • 7.2. Insulin Pens
  • 7.3. Insulin Pumps
  • 7.4. Insulin Syringes

8. Human Insulin Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Gestational Diabetes
  • 8.3. Type 1 Diabetes
  • 8.4. Type 2 Diabetes

9. Human Insulin Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Human Insulin Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Insulin Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Insulin Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Insulin Maker GeneSys to invest USD 50-60 mn to Set up Plant in Hyderabad
    • 13.3.2. Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes
    • 13.3.3. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Albireo Pharma, Inc. by Ipsen
  • 2. B. Braun Melsungen AG
  • 3. Biocon Limited
  • 4. Bristol-Myers Squibb Company
  • 5. Cadila Pharmaceuticals Limited
  • 6. Eli Lilly and Company
  • 7. Eris Lifesciences Ltd.
  • 8. Gan & Lee Pharmaceuticals Co., Ltd.
  • 9. Glenmark Pharmaceuticals Ltd.
  • 10. Gulf Pharmaceutical Industries
  • 11. Innova Life Sciences Private Limited
  • 12. Lupin Limited
  • 13. MannKind Corporation
  • 14. Merck KGaA
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Shreya Life Sciences Pvt Ltd.
  • 19. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 20. Torrent Pharmaceuticals Ltd.
  • 21. Wockhardt Limited
  • 22. Zhuhai United Laboratories Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. HUMAN INSULIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN INSULIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HUMAN INSULIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HUMAN INSULIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN INSULIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN INSULIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY BASAL OR LONG-ACTING INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY BIOSIMILAR INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY MIXED INSULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HUMAN INSULIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY INSULIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY DELIVERY DEVICES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM HUMAN INSULIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. HUMAN INSULIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. HUMAN INSULIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023